A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia

[1]  S. Cremers,et al.  Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma , 2015, Clinical Cancer Research.

[2]  Q. Wen,et al.  Aurora kinase A is required for hematopoiesis but is dispensable for murine megakaryocyte endomitosis and differentiation. , 2015, Blood.

[3]  R. Poon,et al.  Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe , 2015, Oncotarget.

[4]  Traci M. Blonquist,et al.  A Phase I Study of the Aurora a Kinase Inhibitor Alisertib in Combination with 7+3 Induction Chemotherapy in Patients with Acute Myeloid Leukemia , 2014 .

[5]  M. Coumar,et al.  Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 – 2013) , 2014, Expert opinion on therapeutic patents.

[6]  J. McCubrey,et al.  Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia , 2014, Cell cycle.

[7]  P. Westervelt,et al.  An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes , 2014, Leukemia research reports.

[8]  H. Mackay,et al.  Phase II study of oral ENMD-2076 administered to patients with ovarian clear cell carcinoma: A trial of the Princess Margaret Phase II Consortium. , 2014 .

[9]  H. Mackay,et al.  A phase II study of oral ENMD-2076 administered to patients (pts) with advanced soft tissue sarcoma (STS). , 2013 .

[10]  J. Cheong,et al.  Aurora A kinase expression is increased in leukemia stem cells, and a selective Aurora A kinase inhibitor enhances Ara-C-induced apoptosis in acute myeloid leukemia stem cells , 2012, The Korean journal of hematology.

[11]  K. Yee,et al.  ENMD-2076 for hematological malignancies , 2012, Expert opinion on investigational drugs.

[12]  H. Hsieh,et al.  Aurora kinase inhibitor patents and agents in clinical testing: an update (2009 – 10) , 2011, Expert opinion on therapeutic patents.

[13]  E. Rego,et al.  High expression of AURKA and AURKB is associated with unfavorable cytogenetic abnormalities and high white blood cell count in patients with acute myeloid leukemia. , 2011, Leukemia research.

[14]  T. Denny,et al.  ENMD-2076 Is an Orally Active Kinase Inhibitor with Antiangiogenic and Antiproliferative Mechanisms of Action , 2010, Molecular Cancer Therapeutics.

[15]  S. Farag,et al.  Clinical Activity of a Novel Multiple Tyrosine Kinase and Aurora Kinase Inhibitor, ENMD-2076, Against Multiple Myeloma: Interim Phase I Trial Results , 2010 .

[16]  G. Shapiro,et al.  Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor, in Patients with Advanced Solid Tumors , 2010, Clinical Cancer Research.

[17]  W. Vainchenker,et al.  Aurora B is dispensable for megakaryocyte polyploidization, but contributes to the endomitotic process. , 2010, Blood.

[18]  Pu Zhang,et al.  PU.1-mediated upregulation of CSF1R is crucial for leukemia stem cell potential induced by MOZ-TIF2 , 2010, Nature Medicine.

[19]  J. Blagg,et al.  Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias , 2010, Leukemia.

[20]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[21]  H. Fujiwara,et al.  Aurora-A kinase: a novel target of cellular immunotherapy for leukemia. , 2008, Blood.

[22]  H. Kantarjian,et al.  Analysis of Aurora kinase A expression in CD34+ blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia , 2008, Journal of hematopathology.

[23]  M. Konopleva,et al.  Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia. , 2008, Blood.

[24]  K. Mills,et al.  Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts , 2008, Haematologica.

[25]  Oliver Gautschi,et al.  Aurora Kinases as Anticancer Drug Targets , 2008, Clinical Cancer Research.

[26]  Feimeng Zheng,et al.  Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia. , 2008, Blood.

[27]  H. Koeffler,et al.  AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. , 2007, Blood.

[28]  Taizo Tasaka,et al.  A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia , 2007, Molecular Cancer Therapeutics.

[29]  D. Bergstrom,et al.  MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. , 2007, Blood.

[30]  D. Bergstrom,et al.  MK-0457, a Novel Multikinase Inhibitor, Is Active in Patients with Chronic Myeloid Leukemia (CML) and Acute Lymphocytic Leukemia (ALL) with the T315I BCR-ABL Resistance Mutation and Patients with Refractory JAK-2 Positive Myeloproliferative Diseases (MPD). , 2006 .

[31]  D. Hedley,et al.  Whole blood fixation and permeabilization protocol with red blood cell lysis for flow cytometry of intracellular phosphorylated epitopes in leukocyte subpopulations , 2005, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[32]  G. Mills,et al.  Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias , 2004, Leukemia.

[33]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  A. Khwaja,et al.  PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kB, MAPkinase and p53 pathways , 2005, Leukemia.

[35]  M. Carroll,et al.  Survival of acute myeloid leukemia cells requires PI3 kinase activation. , 2003, Blood.

[36]  E. Estey,et al.  Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes , 2002, Cancer.

[37]  H. Serve,et al.  Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia , 2002, Leukemia.

[38]  M. Caligiuri,et al.  Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. , 2001, Cancer research.

[39]  R. Arceci,et al.  Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells. , 2001, Blood.

[40]  B. Cheson,et al.  Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.

[41]  S. Rafii,et al.  Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. , 2000, The Journal of clinical investigation.

[42]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[43]  S. Ergün,et al.  Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. , 1997, Blood.

[44]  L. Stempora,et al.  CD117/CD34 expression in leukemic blasts. , 1996, American journal of clinical pathology.

[45]  M. Minden,et al.  Expression of the CSF‐1 gene in the blast cells of acute myeloblastic leukemia: Association with reduced growth capacity , 1988, Journal of cellular physiology.

[46]  E. Vellenga,et al.  Expression of the macrophage colony-stimulating factor and c-fms genes in human acute myeloblastic leukemia cells. , 1988, The Journal of clinical investigation.

[47]  H. Preisler,et al.  Expression of the protooncogenes c-myc, c-fos, and c-fms in acute myelocytic leukemia at diagnosis and in remission. , 1987, Cancer research.

[48]  D. Matei,et al.  ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer. , 2013, European journal of cancer.

[49]  山本 幸也,et al.  Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies , 2002 .

[50]  E. Estey,et al.  bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 21, 2013. For personal use , 2000 .